S
Sarah A. Moberley
Researcher at Charles Darwin University
Publications - 23
Citations - 1670
Sarah A. Moberley is an academic researcher from Charles Darwin University. The author has contributed to research in topics: Pneumococcal polysaccharide vaccine & Vaccination. The author has an hindex of 11, co-authored 22 publications receiving 1555 citations. Previous affiliations of Sarah A. Moberley include Ministry of Health (New South Wales) & Papua New Guinea Institute of Medical Research.
Papers
More filters
Journal ArticleDOI
Vaccines for preventing pneumococcal infection in adults.
TL;DR: Evidence supporting the recommendation for PPV to prevent IPD in adults is provided, with strong evidence of PPV efficacy against IPD found, and vaccine efficacy against primary outcomes appeared poorer in adults with chronic illness.
Reference EntryDOI
Vaccines for preventing pneumococcal infection in adults (Review)
TL;DR: This meta-analysis provides evidence supporting the recommendation for PPV to prevent all-cause pneumonia or mortality in adults and provides evidence for protection against IPD in populations for whom the vaccine is currently utilised.
Journal ArticleDOI
Vaxtracker: Active on-line surveillance for adverse events following inactivated influenza vaccine in children
Patrick Cashman,Sarah A. Moberley,Craig B Dalton,Jody Stephenson,Elissa Elvidge,Michelle Butler,David N Durrheim +6 more
TL;DR: Vaxtracker as mentioned in this paper is a web-based survey for active post marketing surveillance of adverse events following immunisation, which is designed to efficiently monitor vaccine safety of new vaccines by early signal detection of serious adverse events.
Journal ArticleDOI
Quality improvement intervention to increase adherence to ART prescription policy at HIV treatment clinics in Lusaka, Zambia: A cluster randomized trial.
Elizabeth A. McCarthy,Hamsa Subramaniam,Margaret L. Prust,Marta R. Prescott,Felton Mpasela,Albert Mwango,Leah Namonje,Crispin Moyo,Benjamin Chibuye,Jan van den Broek,Lindsey Hehman,Sarah A. Moberley +11 more
TL;DR: A more patient-centred service delivery schedule of three-month prescription refills for stable patients is viable and should be encouraged in Zambia’s urban clinics.
Journal ArticleDOI
PneuMum: Impact from a randomised controlled trial of maternal 23-valent pneumococcal polysaccharide vaccination on middle ear disease amongst Indigenous infants, Northern Territory, Australia
Michael J. Binks,Sarah A. Moberley,Anne Balloch,Amanda J. Leach,Sandra Nelson,Kim M. Hare,C. Wilson,Peter S. Morris,Jane Nelson,Mark D. Chatfield,Mimi L.K. Tang,Paul J. Torzillo,Jonathan R. Carapetis,E. Kim Mulholland,Ross M. Andrews +14 more
TL;DR: In a high risk population, this study was unable to demonstrate efficacy of 23 vPPV in pregnancy against the co-primary outcomes of either all-cause infant ear disease or 23vPPV-type nasopharyngeal carriage at age 7 months.